Vaxart (OTCMKTS:VXRT) Stock Crosses Below 200 Day Moving Average – Here’s What Happened

Vaxart, Inc. (OTCMKTS:VXRT) shares passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.63 and traded as low as $0.44. Vaxart shares last traded at $0.4501, with a volume of 443,285 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Zacks Research upgraded shares of Vaxart to a “hold” rating in a report on Thursday, July 9th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat, the stock has an average rating of “Hold”.

Vaxart Price Performance

The business’s fifty day moving average is $0.57 and its 200-day moving average is $0.63. The firm has a market cap of $114.16 million, a PE ratio of 3.13 and a beta of 1.09.

Vaxart (OTCMKTS:VXRT) last released its earnings results on Thursday, May 7th. The biotechnology company reported $0.02 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.02. Vaxart had a net margin of 14.51% and a return on equity of 61.43%. The firm had revenue of $39.23 million for the quarter, compared to analysts’ expectations of $50.50 million. Analysts forecast that Vaxart, Inc. will post -0.68 EPS for the current year.

Hedge Funds Weigh In On Vaxart

Institutional investors have recently bought and sold shares of the company. Marshall Wace LLP purchased a new stake in Vaxart in the second quarter worth $794,000. Jones Financial Companies Lllp lifted its position in shares of Vaxart by 276,364.7% during the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock valued at $196,000 after buying an additional 478,111 shares during the last quarter. Goldman Sachs Group Inc. purchased a new position in shares of Vaxart during the 1st quarter valued at $31,000. Creative Planning bought a new position in shares of Vaxart during the 2nd quarter worth $33,000. Finally, Invesco Ltd. increased its holdings in Vaxart by 93.1% in the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 70,568 shares during the last quarter. Hedge funds and other institutional investors own 18.05% of the company’s stock.

Vaxart Company Profile

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.